<DOC>
	<DOCNO>NCT00003436</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy kill cancer cell . It yet know whether chemotherapy effective without bone marrow transplantation acute myeloid leukemia . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy without bone marrow transplantation treat child acute myeloid leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Bone Marrow Transplantation Treating Children With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare two induction schedule respect achievement duration remission , survival , toxicity , supportive care requirement child previously untreated acute myeloid leukemia . - Compare 4 versus 5 course treatment total ( final course either chemotherapy bone marrow transplantation ) respect remission duration , relapse rate , death remission , overall survival patient . - Compare value allogeneic bone marrow transplantation versus conventional chemotherapy respect remission duration , relapse rate , death remission , overall survival patient . - Reduce toxicity without compromise survival restrict number patient receive bone marrow transplant study . OUTLINE : This randomize study . Patients first randomize one two induction treatment arm . - Induction Arm I : Patients receive 2 course cytarabine IV push every 12 hour day 1-10 1-8 ( 20 16 dos ) ; daunorubicin IV 6 hour day 1 , 3 , 5 ; etoposide IV 4 hour day 1-5 ( 5 dos ) . - Induction Arm II : Patients receive 2 course mitoxantrone IV 6 hour day 1 , 3 , 5 ; cytarabine IV push every 12 hour day 1-10 1-8 ( 20 16 dos ) ; etoposide IV 4 hour day 1-5 ( 5 dos ) . Patients CNS disease diagnosis receive 3 course triple intrathecal therapy ( methotrexate , cytarabine , hydrocortisone ) , one first 3 course chemotherapy . Patients CNS disease receive least 6 course intrathecal therapy ( 2 course per week ) , monthly course final course chemotherapy complete . Patients complete response induction course 2 continue study . Patients complete response induction course 2 take study eligible current Medical Research Council ( MRC ) refractory/relapse study another therapy . Course 3 : All patient continue study receive amsacrine IV 1 hour daily day 1-5 , cytarabine continuous IV infusion daily day 1-5 , etoposide IV 4 hour day 1-5 course 3 . After course 3 , patient assign two risk group : good risk patient , standard poor risk patient . Standard poor risk patient match sibling donor good risk patient randomized consolidation arm I II . - Arm I : Patients receive mitoxantrone IV 6 hour day 1-5 cytarabine IV 2 hour every 12 hour day 1-3 ( 4 course chemotherapy total ) . - Arm II : Patients receive cytarabine IV 3 hour every 12 hour day 1 , 2 , 8 , 9 , asparaginase subcutaneous infusion 3 hour completion last cytarabine dos day 2 9 , follow course mitoxantrone cytarabine arm I ( 5 course chemotherapy total ) . Standard poor risk child match sibling donor randomize arm III IV . - Arm III : Patients receive consolidation treatment ( 3 course chemotherapy total ) plus bone marrow transplantation . - Arm IV : Patients receive cytarabine asparaginase arm II ( 4 course chemotherapy total ) plus bone marrow transplantation . Patients follow least 1 year . PROJECTED ACCRUAL : Approximately 2,000 patient accrue study 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Amsacrine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Histologically confirm de novo secondary acute myeloid leukemia ( AML ) Aggressive myelodysplastic syndrome ( refractory anemia excess blast ( RAEB ) RAEB transformation ) intensive AML therapy consider appropriate Acute promyelocytic leukemia ( also enter protocol MRCATRA ) No chronic myeloid leukemia blast transformation Must consider suitable intensive chemotherapy PATIENT CHARACTERISTICS : Age : Under 16 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No concurrent active malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy leukemia Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2000</verification_date>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>